Hemophilia A patients require frequent Factor VIII injections , which create a significant burden for these individuals. The rFVIIIFc molecule is to extend to the potential protection from bleeding and the frequency of injections for both prophylaxis and on-demand therapy in hemophilia A. Preclinical studies showed improved half-life of rFVIIIFc, monomeric monomeric Fc Biogen Idec examines fusion technology check information http://www.sildenafilini.com . True. We welcome rFVIIIFc bring in phase with Biogen Idec and thus adding another important cooperative project ongoing recombinant factor IX Fc fusion protein clinical program inspires the innovative rFVIIIFc program has great potential in offering true. Value hemophilia A patients, and is thus a prioritized therapeutic and business area within Biovitrum, said Peter Edman, CSO of Biovitrum.
Workers and employers concerned for COBRA extensionThis information was of kaiserhealthnews.org courtesy of the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at Kaiser health news.
On PharmacorThe newly redesigned Pharmacor consultancy offers its customers of the biopharmaceutical industry that most up-to-date information on economically significant disease Subjects.